IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology, has announced its preliminary financial results for the three and six months ended June 30, 2025. The company reported expected product sales of approximately $525,000 for the three months ended June 30, 2025. Additionally, for the six-month period ended June 30, 2025, product sales were approximately $1.25 million, a decrease from $1.65 million during the same period in 2024. This decline is attributed to lower than expected shipments in the second quarter of 2025, although more than $200,000 in delayed shipments are anticipated to be delivered and recorded in the third quarter of 2025. The order flow was not affected by the conflict between Israel and Iran, though certain non-U.S. customer shipments experienced temporary delays, which have since resumed. Payments for these delayed orders were received during the second quarter and recorded as deferred sales on the company's balance sheet. The U.S. market was unaffected due to sufficient inventory levels maintained by IceCure. IceCure plans to release its comprehensive second quarter and first half 2025 financial results in August 2025 and does not intend to issue preliminary financial results on a quarterly basis unless required.